EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, NetScientific's enterprise value is €19.79 Mil.
NetScientific's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €1.60 Mil. Therefore, NetScientific's EV-to-Revenue for today is 12.35.
The historical rank and industry rank for NetScientific's EV-to-Revenue or its related term are showing as below:
STU:NTK1'
s EV-to-Revenue Range Over the Past 10 Years
Min: -39.88 Med: 13.86 Max: 557.47
Current: 12.24
During the past 13 years, the highest EV-to-Revenue of NetScientific was 557.47. The lowest was -39.88. And the median was 13.86.
STU:NTK1's EV-to-Revenue is ranked worse than 60.79% of 1033
companies
in the Biotechnology industry
Industry Median: 7.68
vs STU:NTK1: 12.24
As of today (2024-04-26), NetScientific's stock price is €0.68.
NetScientific's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.07. Therefore, NetScientific's PS Ratio for today is 10.00.
NetScientific EV-to-Revenue Historical Data
The historical data trend for NetScientific's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NetScientific's EV-to-Revenue
For the Biotechnology subindustry, NetScientific's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NetScientific's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NetScientific's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where NetScientific's EV-to-Revenue falls into.
NetScientific's current Enterprise Value is €19.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NetScientific's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €1.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NetScientific's share price for today is €0.68.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was €0.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NetScientific EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of NetScientific's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
NetScientific PLC is a transatlantic healthcare technology company. The group is focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients, Glucosense a provider of a non-invasive glucose monitoring wearable device, Vortex Biosciences which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing, and Glycotest which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:NTK1 has been successfully added to your 